- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2020-03-01
2021-07-25
2021-08-25
8
NCT04310111
First People's Hospital of Hangzhou
First People's Hospital of Hangzhou
INTERVENTIONAL
EUS-RFA for Unresectable Pancreatic Cancer
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.
evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2020-03-10 | N/A | 2021-08-27 |
2020-03-15 | N/A | 2021-08-30 |
2020-03-17 | N/A | 2021-08 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Treatment
Allocation:
Na
Interventional Model:
Single Group
Masking:
None
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: EUS-RFA Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was a | PROCEDURE: EUS-RFA
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Tumor size | Tumor size | 2 years |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Serum levels of CA19-9 | Serum levels of CA19-9 before and after surgery | 2 years |
| survival rate | including Overall survival | 2 years |
| Adverse events | Adverse events | 2 years |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
20 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
